CRYBG3

Across TCGA pan-cancer cohorts, CRYBG3 mass-spec protein is linked to patient survival in 6 of 34 cancer types, making it a survival-associated CRYBG3 data layer compared with 26 for mass-spec protein and 9 for mutation status.

The strongest signal is observed in clear cell renal cell carcinoma (CCRCC), where higher CRYBG3 mass-spec protein is associated with worse disease-free survival. In most high-consensus cancer types, elevated CRYBG3 expression acts as an unfavorable survival marker, although some lineages such as PDAC and HNSC show a favorable association.

CCRCC, GBM, and UCEC are the cancer types where CRYBG3 mass-spec protein most reproducibly stratifies survival.

mass-spec protein survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
CCRCC	DFS	Median	II,III,IV	0.128	0.952	.003	30	view →
GBM	OS	Median	All	0.731	0.895	.002	16	view →
UCEC	OS	Median	III,IV	0.492	0.884	.031	16	view →
PDAC	DFS	Median	II,III,IV	0.502	0.306	.007	9	view →
HNSC	OS	Median	All	0.804	0.637	.032	2	view →
LSCC	DFS	Median	All	0.905	1.000	.048	1	view →

Pink = unfavorable, green = favorable. Showing the 6 strongest of 6 lineages.

CRYBG3–CCRCC (DFS)

Open the CCRCC breakdown →